Purpose: The purpose of this article was to present the case of a pelvic abscess, which developed after an emergency cesarean section followed by a hysterectomy, to identify the risk factors, and describe a minimally invasive technique for abscess drainage.
Case report: We present a 30-year-old patient at 35 + 4 weeks gestation who had an emergency cesarean section. The indication for the cesarean section were four previous cesarean sections. She had severe postpartum bleeding due to uterine atony and disseminated intravascular coagulopathy, which did not resolve with conservative treatment. A few days later, a pelvic abscess formed and complicated the post-operative recovery.
Conclusion: A pelvic abscess is a rare complication following obstetrics surgery; however, it is important to take
Background: Tools to support clinical decision making regarding breast cancer (BC) are becoming more available to clinicians. NHS PREDICT is a freely available webbased tool for prognostication and assistance in BC management. Recent research shows doubt in using the tool for BC subtypes. There is fear over the possibility of overor undertreatment of patients. Methods: Ninety-four patients regardless of their ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal growth factor receptor 2) status were included in this study. Through using the platform NHS PREDICT 2.0 we evaluated through the pilot study the prediction of patients with newly diagnosed breast cancer. We evaluated the prediction of 10-year survival, benefit of surgical treatment, treatment with hormonal therapy, transtuzumab treatment and benefit of chemotherapy. Results: The median age at diagnosis was 60.10 years (SD 14.4). Patients were classified according to hormonal status: i) ERþ BC (n ¼ 69), ii) ERþ and HER2þ BC (n ¼ 8), iii) ER-, but HER2þ BC (n ¼ 7) and iv) triple negative BC (n ¼ 10). Overall 10-year survival for ERþ, HER2-was 86.1 % (benefit of adjuvant chemotherapy adding 2.8 %), for ER-and HER2þ 83.7% (benefit of adjuvant chemotherapy adding 7.0 %) and for TNBC 77.4% (benefit of adjuvant chemotherapy 5.5 %). Overall data is represented in Table . Conclusions: This pilot analysis estimates that overall survival was in accordance to available treatment data. TNBC 10-year survival was appropriate (decreased), but the tool estimated very low chemotherapy benefits for TNBC patients in comparison to other patient groups thus posing the risk of patient undertreatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.